<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="971">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 01, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01846156</url>
  </required_header>
  <id_info>
    <org_study_id>52103</org_study_id>
    <secondary_id>52013</secondary_id>
    <nct_id>NCT01846156</nct_id>
  </id_info>
  <brief_title>New Magnesium Sulphate Protocol for Pre-eclampsia</brief_title>
  <official_title>The Best Magnesium Sulphate Protocol for Severe Pre-eclampsia : A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <authority>Egypt: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      there is a standard magnesium sulphate protocol and newer protocols for pre-eclampsia, we
      need to make a trial to find the best protocol
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of our study is to assess the comparative effects of three regimens for the
      administration of magnesium sulfate when used for the care of women with severe
      pre-eclampsia.

      The study will include 240 pregnant women presenting to the casualty unit with criteria of
      severe preeclampsia in the form of one of the criteria:-

        -  Systolic blood pressure ≥ 160.

        -  Diastolic blood pressure ≥ 110.

        -  Proteinuria &gt; +2 by dip stick.

        -  Presence of alarming symptoms (headache, visual disturbance, epigastric pain, vaginal
           bleeding).

        -  Fetal growth restriction (IUGR).

      After obtaining an informed consent the patients will be subjected to the following:

        -  Careful history taking including age, parity, gestational age.

        -  Complete physical examination and assessment of the blood pressure.

        -  Urine analysis by dipstick.

        -  All women will take initial MgSO4 (6 grams of MgSO4 on 250 ml ringer solutions over 20
           minutes by IV drip) .

      Using Random Number Table, the sample size will be divided into three categories:-

        -  Category A : 80 patients given full dose of maintenance MgSO4 (4 grams of MgSO4 on 250
           ml ringer solution over 4 hours every 4 hours by IV drip for 24 hours) in the
           postpartum period.

        -  Category B : 80 patients given abbreviated doses of MgSO4 (4 grams of MgSO4 on 250 ml
           ringer solution over 4 hours every 4 hours by IV drip only for 12 hours) in the
           postpartum period.

        -  Category C : 80 patients who will take only loading dose of MgSO4 (6 grams of MgSO4 on
           250 ml ringer solutions over 20 minutes) with no postpartum maintenance sulfate.

      Inclusion criteria:

        -  Pregnant females ≥20 weeks of gestation.

        -  Pregnant females with criteria of severe pre-eclampsia.

        -  Single or multi-fetal pregnancy.

        -  Primigravida or Multigravida.

      Exclusion criteria:

        -  Pregnant females &lt; 20 weeks gestation.

        -  Pregnant females with history of epilepsy.

        -  Pregnant females with diabetes.

        -  Pregnant females with chronic hypertension.

        -  Pregnant females with renal disease.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">April 2014</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>duration of MgSo4 treatment</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>treatment duration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICU admission</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>ICU admission</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">240</enrollment>
  <condition>Pre-eclampsia</condition>
  <arm_group>
    <arm_group_label>Abrreviated MgSO4 protocol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>- Category B : 80 patients given abbreviated doses of MgSO4 (4 grams of MgSO4 on 250 ml ringer solution over 4 hours every 4 hours by IV drip only for 12 hours) in the postpartum period.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No maintenance protocol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>- Category C : 80 patients who will take only loading dose of MgSO4 (6 grams of MgSO4 on 250 ml ringer solutions over 20 minutes) with no postpartum maintenance sulfate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard MgSO4 protocol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>- Category A : 80 patients given full dose of maintenance MgSO4 (4 grams of MgSO4 on 250 ml ringer solution over 4 hours every 4 hours by IV drip for 24 hours) in the postpartum period.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MgSO4</intervention_name>
    <description>A randomized controlled study that compare three regimens for administration of MgSO4 used for the cases of severe pre-eclampsia that will be performed in the Obstetrics &amp; Gynecology Department, Kasr Al-Ainy Hospital, Cairo University</description>
    <arm_group_label>Abrreviated MgSO4 protocol</arm_group_label>
    <arm_group_label>No maintenance protocol</arm_group_label>
    <arm_group_label>standard MgSO4 protocol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnant females ≥20 weeks of gestation.

          -  Pregnant females with criteria of severe pre-eclampsia.

          -  Single or multi-fetal pregnancy.

          -  Primigravida or Multigravida.

        Exclusion Criteria:

          -  Pregnant females &lt; 20 weeks gestation.

          -  Pregnant females with history of epilepsy.

          -  Pregnant females with diabetes.

          -  Pregnant females with chronic hypertension.

          -  Pregnant females with renal disease.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>42 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Waleed El-khayat, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cairo University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kasr Alainy hospital</name>
      <address>
        <city>Cairo</city>
        <zip>12311</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <lastchanged_date>August 21, 2014</lastchanged_date>
  <firstreceived_date>May 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Waleed El-khayat</investigator_full_name>
    <investigator_title>Assistant Professor of Obstetrics &amp; Gynecology</investigator_title>
  </responsible_party>
  <keyword>convulsion rate</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Eclampsia</mesh_term>
    <mesh_term>Pre-Eclampsia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
